AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Caprice Resources

0.083

-0.003-3.49%

Volume:2.11M

Turnover:175.44K

Market Cap:58.54M

PE:-10.67

High:0.086

Open:0.086

Low:0.081

Close:0.086

52wk High:0.160

52wk Low:0.042

Shares:705.32M

Float Shares:644.73M

Volume Ratio:0.57

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:-16.11%

ROA:-9.70%

PB:2.30

PE(LYR):-10.67

Loading ...

Overview Company News Filings

Caprice Resources Finds High Grade Gold Mineralization in Western Australia Project, Shares Up 3%

MT Newswires Live

Caprice Resources Ltd-Drilling Confirms Extensions to High-Grade Gold at Vadrians

THOMSON REUTERS

A Look At Carpenter Technology (CRS) Valuation After Raised Guidance And Strong Quarterly Earnings

Simply Wall St.

Cowbell Launches in Australia, Bringing AI-Powered Cyber Protection backed by the Financial Strength of Zurich

Caprice Resources Ltd-Appointment of Highly Experienced Exploration Manager

THOMSON REUTERS

Gstar's Solar Module Series First to Achieve India's New BIS Certification

Is Dividend Hike, Investment-Grade Rating and New Debt Deal Altering The Investment Case For Carpenter Technology (CRS)?

Simply Wall St.

BUZZ-Australia's Caprice Resources rises on high-grade gold find

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

We Think Caprice Resources (ASX:CRS) Can Afford To Drive Business Growth

Simply Wall St.

Caprice Resources Ltd-Comet Exploration Project Acquisition Completes

THOMSON REUTERS

Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma

Caprice Resources Starts Air-Core Drilling at Western Australia Project; Shares Down 4%

MT Newswires Live

XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications

$700 Million Refinancing Could Be A Game Changer For Carpenter Technology (CRS)

Simply Wall St.

Carpenter Technology Closes $700 Million Senior Notes Offering

MT Newswires Live

PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRS.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRS.AU\",,,,,undefined,":{"symbol":"CRS.AU","market":"AU","secType":"STK","nameCN":"Caprice Resources","latestPrice":0.083,"timestamp":1770959520000,"preClose":0.086,"halted":0,"volume":2112345,"delay":0,"changeRate":-0.03488372093023243,"nameEN":"Caprice Resources","floatShares":644725953,"shares":705318814,"eps":-0.00778,"marketStatus":"Market Closed","change":-0.003,"latestTime":"02-13 16:12:00 AEDT","open":0.086,"high":0.086,"low":0.081,"amount":175444,"amplitude":0.05814,"askPrice":0.085,"askSize":51000,"bidPrice":0.083,"bidSize":20059,"shortable":3,"etf":0,"ttmEps":-0.00778,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771196400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.086,"openAndCloseTimeList":[[1770937200000,1770958800000]],"volumeRatio":0.5668353406249245,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CRS.AU\",,,,,undefined,":{"symbol":"CRS.AU","floatShares":644725953,"roa":"-9.70%","roe":"-16.11%","lyrEps":-0.00778,"volumeRatio":0.5668353406249245,"shares":705318814,"dividePrice":0,"high":0.086,"amplitude":0.05814,"preClose":0.086,"low":0.081,"week52Low":0.042,"pbRate":"2.30","psRate":"2840.03","week52High":0.16,"institutionHeld":0,"latestPrice":0.083,"committee":-0.435427,"eps":-0.00778,"divideRate":0,"volume":2112345,"delay":0,"ttmEps":-0.00778,"open":0.086,"prevYearClose":0.094,"prevWeekClose":0.09,"prevMonthClose":0.09,"prevQuarterClose":0.094,"fiveDayClose":0.09,"twentyDayClose":0.105,"sixtyDayClose":0.155,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRS.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-08-14","symbol":"CRS.AU","defaultRemindTime":1597363200000,"type":"split","dateTimestamp":1597327200000,"forFactor":2147483647,"toFactor":2147483647,"ratio":0.925577}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRS.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRS.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610916603","title":"Caprice Resources Finds High Grade Gold Mineralization in Western Australia Project, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610916603","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610916603?lang=en_us&edition=fundamental","pubTime":"2026-02-11 09:15","pubTimestamp":1770772514,"startTime":"0","endTime":"0","summary":"Caprice Resources  found high-grade gold mineralization during a recent drilling at its Island gold project's Vadrians system in Western Australia, according to a Wednesday Australian bourse filing.The results were up to nine meters at 7.3 grams per tonne grade of gold from 148 meters, and seven meters at 5.1 g/t gold from 297 meters.The company has completed phase four of the drilling program, with assays still pending for five diamond holes and 160 air core holes. Results are expected to be received in batches through February and March.The company added that a follow-up reverse circulation drilling targeting further Vadrians growth in both the northern strike extensions and additional depth extensions is scheduled to commence in February.The company's shares rose 3% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","GDXJ","1OZmain","WRN","XJO.AU","BK4588","GLDM","BK4168","XKO.AU","CRS.AU","GDX","IAU","XME","BK4585","SGOL","GLL","BK4535","XAO.AU","UGL","BK4504"],"gpt_icon":0},{"id":"2610679853","title":"Caprice Resources Ltd-Drilling Confirms Extensions to High-Grade Gold at Vadrians","url":"https://stock-news.laohu8.com/highlight/detail?id=2610679853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610679853?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:16","pubTimestamp":1770758185,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUE9LH7BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","CRS.AU"],"gpt_icon":0},{"id":"2610266657","title":"A Look At Carpenter Technology (CRS) Valuation After Raised Guidance And Strong Quarterly Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2610266657","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610266657?lang=en_us&edition=fundamental","pubTime":"2026-02-10 03:16","pubTimestamp":1770664572,"startTime":"0","endTime":"0","summary":"Carpenter Technology (CRS) is back in focus after its latest quarterly report, which paired higher sales and net income with raised operating income guidance for both the third quarter and full fiscal year 2026.\nSee our latest analysis for Carpenter Technology.\nThe raised guidance and recent buyback sit alongside strong price action, with a 17.3% 7 day share price return, 13.2% 90 day share price return and a very large 5 year total shareholder return. Taken together, these factors suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/a-look-at-carpenter-technology-crs-valuation-after-raised-gu","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/a-look-at-carpenter-technology-crs-valuation-after-raised-gu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRS.AU","CRS"],"gpt_icon":0},{"id":"2609555371","title":"Cowbell Launches in Australia, Bringing AI-Powered Cyber Protection backed by the Financial Strength of Zurich","url":"https://stock-news.laohu8.com/highlight/detail?id=2609555371","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609555371?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:46","pubTimestamp":1770353160,"startTime":"0","endTime":"0","summary":"Appoints Industry veterans Anthony Wall, Alric Lal to lead Underwriting & Distribution. SYDNEY, Feb. 6, 2026 /PRNewswire/ -- Cowbell, a leading provider of adaptive cyber and specialty insurance solutions for global small and mid-market organizations, today announced its official launch in the Australian market, introducing Prime One, a standalone cyber insurance programme designed for small and medium-sized enterprises  with up to A$100 million in annual turnover. Policies are written on Zurich Australian Insurance Ltd paper, pairing Zurich's financial backing and local presence with Cowbell's AI-powered underwriting platform, in-house claims capabilities, and comprehensive resiliency services.Prime One, which can be quoted, bound and issued in less than 5 minutes, is now available through licensed insurance brokers, giving Australian businesses a straightforward way to understand their digital risks and secure protection that adapts as those risks evolve.\"Cyber protection shouldn't b","market":"us","thumbnail":"https://mma.prnewswire.com/media/2803254/Cowbell_Cyber_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2803254/Cowbell_Cyber_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cowbell-launches-in-australia-bringing-ai-powered-cyber-protection-backed-by-the-financial-strength-of-zurich-302680993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B66KJ199.SGD","LU0963586101.USD","XJO.AU","IE00B19Z4B17.USD","BK7095","BK4187","CRS.AU","IE00B7SZL793.SGD","LU2065731478.USD","XKO.AU","CRS","XAO.AU","BK4006"],"gpt_icon":0},{"id":"2609458027","title":"Caprice Resources Ltd-Appointment of Highly Experienced Exploration Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=2609458027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609458027?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:28","pubTimestamp":1770330524,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUE8CBVPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRS.AU","BK7095"],"gpt_icon":0},{"id":"2608831985","title":"Gstar's Solar Module Series First to Achieve India's New BIS Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=2608831985","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608831985?lang=en_us&edition=fundamental","pubTime":"2026-02-02 12:00","pubTimestamp":1770004800,"startTime":"0","endTime":"0","summary":"SINGAPORE, Feb. 2, 2026 /PRNewswire/ -- Gstar announced that its 183N, 210RN series photovoltaic  modules have achieved certification under India's latest Bureau of Indian Standards  requirements, including IS14286:2023. The certification marks an important milestone in Gstar's ongoing commitment to product safety and quality, regulatory compliance, and participation in international PV markets.In India, BIS certification is mandatory for all PV modules under the Compulsory Registration Scheme . Only BIS-certified modules are eligible for legal import, sale, and deployment in India, including government and public-sector projects. Achieving certification among the first under the new standard, Gstar's modules are confirmed to meet India's latest technical requirements through testing and audits, demonstrating the manufacturer's strong capabilities in quality management, production consistency, and compliant operations.Gstar's newly certified modules combine N-type high-efficiency cells","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2873274/20260127163323_415_121.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2873274/20260127163323_415_121.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/gstars-solar-module-series-first-to-achieve-indias-new-bis-certification-302674942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNDmain","BK4006","CRS","CRS.AU","IE00B66KJ199.SGD","LU0963586101.USD","BK7095","BK4187","BK7129","IE0031619046.USD","LU2065731478.USD","BIS.AU","BIS","IE00B19Z4B17.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2604854551","title":"Is Dividend Hike, Investment-Grade Rating and New Debt Deal Altering The Investment Case For Carpenter Technology (CRS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604854551","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604854551?lang=en_us&edition=fundamental","pubTime":"2026-01-19 12:34","pubTimestamp":1768797250,"startTime":"0","endTime":"0","summary":"Carpenter Technology Corporation recently declared a past quarterly cash dividend of US$0.20 per share, payable on March 5, 2026, to shareholders of record as of January 27, 2026, while also closing a US$700 million senior notes offering at 5.625% interest maturing in 2034 and receiving a Fitch credit rating upgrade to BBB-.\nThis combination of an ongoing dividend, long-term financing, and an investment-grade credit rating signals stronger balance sheet flexibility and an emphasis on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/is-dividend-hike-investment-grade-rating-and-new-debt-deal-a","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/is-dividend-hike-investment-grade-rating-and-new-debt-deal-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRS","CRS.AU"],"gpt_icon":0},{"id":"2604017809","title":"BUZZ-Australia's Caprice Resources rises on high-grade gold find","url":"https://stock-news.laohu8.com/highlight/detail?id=2604017809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604017809?lang=en_us&edition=fundamental","pubTime":"2026-01-19 11:36","pubTimestamp":1768793765,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Caprice Resources rises on high-grade gold find** Caprice Resources CRS.AX rises 4.8% to A$0.11, highest since January 9** Gold explorer reports high-grade gold drilling results from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nL6N3YK07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","CRS.AU"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","IE00B3S45H60.SGD","LU0211328371.USD","LU0345770993.USD","LU1670627923.USD","IE00BFXG1179.USD","LU1629891620.HKD","ORR.AU","IE0034235295.USD","LU1064131342.USD","LU2065731478.USD","LU1084165304.USD","IE00BHPRN162.USD","CRS.AU","BK4534","LU0943347566.SGD","ORR","LU0208291251.USD","IND","LU2756315664.SGD","LU0417517546.SGD","LU0006306889.USD","LU0106831901.USD","IE00BKVL7J92.USD","LU1974910355.USD","IE00BN8TJ469.HKD","IND.AU","LU0820562030.AUD","LU0345769631.USD","LU0345770308.USD","LU0170899867.USD","LU2746668461.USD","ACR.AU","LU2023250843.SGD","BK4581","LU0820561818.USD","LU2430703095.HKD","CRS","LU1244550494.USD","ACR","LU2264538146.SGD","CR","LU0868494617.USD","BK7508","LU0106261372.USD","LU0251132253.USD","LU2106854487.HKD","LU0683600562.USD","LU0787776722.HKD"],"gpt_icon":0},{"id":"2601824506","title":"We Think Caprice Resources (ASX:CRS) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824506","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824506?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:11","pubTimestamp":1767748304,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Caprice Resources...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-crs/caprice-resources-shares/news/we-think-caprice-resources-asxcrs-can-afford-to-drive-busine","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-crs/caprice-resources-shares/news/we-think-caprice-resources-asxcrs-can-afford-to-drive-busine","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B19Z4B17.USD","BK4006","IE00B66KJ199.SGD","LU0963586101.USD","BK7095","IE00B7SZL793.SGD","LU2065731478.USD","CRS.AU","IE0031619046.USD","BK4187","CRS"],"gpt_icon":0},{"id":"2592462259","title":"Caprice Resources Ltd-Comet Exploration Project Acquisition Completes","url":"https://stock-news.laohu8.com/highlight/detail?id=2592462259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592462259?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:28","pubTimestamp":1766010524,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUE9J0CPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7095","CRS.AU"],"gpt_icon":0},{"id":"2592951573","title":"Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592951573","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592951573?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:00","pubTimestamp":1765933200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application  for XPOVIO  for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma  after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.Antengene has also developed AnTenGager, a proprietary T cell engager 2.0 platform featuring \"2+1\" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-expands-xpovio-indications-in-malaysia-with-approval-in-diffuse-large-b-cell-lymphoma-302643389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","CRS.AU","CRS","IE00B66KJ199.SGD","LU2065731478.USD","IE00B7SZL793.SGD","IND.AU","IE00B19Z4B17.USD","IND","IE0031619046.USD","BK4187","LU0963586101.USD","BK4006"],"gpt_icon":0},{"id":"2589568138","title":"Caprice Resources Starts Air-Core Drilling at Western Australia Project; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589568138","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589568138?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:17","pubTimestamp":1764893842,"startTime":"0","endTime":"0","summary":"Caprice Resources  started air-core drilling at the Island gold project in Western Australia, according to a Friday filing with the Australian bourse.The program forms part of the 20,000-meter fourth-phase drilling campaign, and will target high-impact strike extensions to the Vadrians deposit and test parallel banded iron formations within the mining lease, the filing said.The company expects completion of the diamond drilling component of the campaign in the fourth quarter, while reverse circulation drilling will continue in parallel, per the filing.Shares fell 4% in morning trade on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7095","WRN","BK4168","XAO.AU","XKO.AU","XJO.AU","CRS.AU"],"gpt_icon":0},{"id":"2588011633","title":"XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011633","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588011633?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:00","pubTimestamp":1764752400,"startTime":"0","endTime":"0","summary":"- XPOVIO  has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma  when used together with dexamethasone , and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma  and as a combination therapy when used together with bortezomib and dexamethasone  for MM patients who received at least one prior therapy.- XPOVIO is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO is set to benefit more patients in Hong Kong.- XPOVIO has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets .Antengene Corporation Limited  is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical t","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/xpovio-approved-in-hong-kong-for-two-additional-indications-in-multiple-myeloma-and-diffuse-large-b-cell-lymphoma-302631561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","LU2065731478.USD","IE0031619046.USD","IE00B7SZL793.SGD","LU0963586101.USD","CRS.AU","IE00B66KJ199.SGD","BK4006","CRS","IND","IND.AU","BK4187","BK7095"],"gpt_icon":0},{"id":"2588035413","title":"Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035413","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035413?lang=en_us&edition=fundamental","pubTime":"2025-12-02 17:00","pubTimestamp":1764666000,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ --Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration  has approved the investigational new drug  application for the Phase Ib/II CLINCH-2 study evaluating ATG-022  in combination with MSD's  anti-PD-1 therapy, KEYTRUDA , as well as ATG-022 in combination with pembrolizumab and chemotherapy.CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive  unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-ind-approval-in-china-for-phase-ibii-study-of-atg-022-cldn18-2-adc-in-combination-with-keytruda-pembrolizumab--chemotherapy-302630014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4181","CRS.AU","IND","IE00B19Z4B17.USD","BK4006","PK","BK4231","LU0963586101.USD","BK4218","BK7095","ORR","ADC","IE00B66KJ199.SGD","LU2065731478.USD","BK4187","ORR.AU","IE0031619046.USD","ADC.AU","IE00B7SZL793.SGD","IND.AU","CRS"],"gpt_icon":0},{"id":"2586782177","title":"Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2586782177","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586782177?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:52","pubTimestamp":1764334320,"startTime":"0","endTime":"0","summary":"BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd.  announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel  , has received new drug marketing approvalfrom the China National Medical Products Administration . This approval is for the treatment of relapsed or refractory Large B-Cell Lymphoma  after two or more lines of systemic therapy. This is the second approved indicationin China for Ina-cel, following its initial approval in November 2023 for the treatment of adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia . This milestone marks the first proprietary CD19 CAR-T product in China with full intellectual property rights to become the only CAR-T cell therapy product in the country that covers both leukemia and lymphoma, the two major hematological oncology indications.Professor Dehui Zou, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences :","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/inaticabtagene-autoleucel-yorwidatm-new-drug-application-for-lymphoma-approved-chinas-innovative-car-t-enters-a-new-era-of-dual-indications-302628059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR.AU","BK4187","BK4022","CAR","IE00B19Z4B17.USD","LU0963586101.USD","BK4006","BK4161","CRS.AU","IE00B66KJ199.SGD","LU2065731478.USD","ORR","IE00B7SZL793.SGD","BK7095","CRS","CR","IE0031619046.USD","BK4230"],"gpt_icon":0},{"id":"2586261792","title":"$700 Million Refinancing Could Be A Game Changer For Carpenter Technology (CRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261792","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261792?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:18","pubTimestamp":1764173892,"startTime":"0","endTime":"0","summary":"Earlier this month, Carpenter Technology Corporation completed a US$700 million private offering of 5.625% senior notes due 2034 and amended its credit agreement to increase revolving commitments to US$500 million and extend the credit facility maturity to 2030.\nThis refinancing initiative is intended to repay higher-interest debt and is expected to enhance the company's financial flexibility through improved liquidity and reduced future interest expenses.\nWe'll explore how Carpenter...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice1-main-header/1585186785008"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/700-million-refinancing-could-be-a-game-changer-for-carpente","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-crs/carpenter-technology/news/700-million-refinancing-could-be-a-game-changer-for-carpente","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","IE00B66KJ199.SGD","CRS.AU","LU0963586101.USD","BK4006","CRS","IE00B7SZL793.SGD","LU2065731478.USD","IE0031619046.USD","BK4187","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2585532163","title":"Carpenter Technology Closes $700 Million Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2585532163","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585532163?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:18","pubTimestamp":1763677121,"startTime":"0","endTime":"0","summary":"Carpenter Technology (CRS) reported late Thursday the closing of its $700 million offering of 5.625% senior notes due 2034.The firm said it plans to use the proceeds to help redeem 6.375% senior notes due 2028 and 7.625% senior notes due 2030.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z4B17.USD","BK4006","IE00B66KJ199.SGD","LU0963586101.USD","BK7095","IE00B7SZL793.SGD","LU2065731478.USD","CRS.AU","IE0031619046.USD","BK4187","CRS"],"gpt_icon":0},{"id":"2584153997","title":"PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2584153997","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584153997?lang=en_us&edition=fundamental","pubTime":"2025-11-20 23:12","pubTimestamp":1763651520,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01  have been accepted for oral presentations at the 2025 American Society of Hematology  Annual Meeting.The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia  and r/r B-cell Non-Hodgkin Lymphoma , including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies  support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.Safety: PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade 1 Cytokine Release Syndrome  and no Grade 1 Immune Effector Cell-Associated Neu","market":"sh","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bios-pmb-ct01-baffr-car-t-data-selected-for-two-oral-presentations-at-67th-ash-2025-annual-meeting-302621280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7111","BK4187","BK7057","BK4022","IE00B66KJ199.SGD","IE00B7SZL793.SGD","CAR","BK4230","ASH.AU","CRS","BK7095","BK7501","LU0963586101.USD","LU2065731478.USD","LU2463526074.USD","HCT.AU","IE00B19Z4B17.USD","ASH","BK4006","BK4109","IE0031619046.USD","CRS.AU","BK4161","CR"],"gpt_icon":0},{"id":"2584906256","title":"Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2584906256","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584906256?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:56","pubTimestamp":1763607360,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 , ATG-037 , and ATG-101 . The company will also share the latest progress on ATG-125 :A B7H3 x PD-L1 targeted therapy featuring\"IO + ADC\"dual-effect molecules for the treatment of solid tumors and its AnTenGagerT-cell engager  technology platform which incorporates steric hindrance masking, along with updates on several key preclinical programs.In addition, guest expert Prof. Xin Wang, Chief Physician, Drug Clinical Trial Center, National Cancer Center / Cancer Hospital of the Chinese Academy of Medica","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-hosts-2025-rd-day-showcasing-encouraging-clinical-data-and-solid-progress-with-investigational-programs-302621100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR.AU","BK4161","BK7096","ORR.AU","LU0963586101.USD","BK4110","BK4097","ACR","CRS.AU","LU2065731478.USD","LU2065732104.USD","ORR","BK4006","BK7508","IE00B19Z4B17.USD","BK4187","BK7095","IND.AU","IE00B7SZL793.SGD","CRS","PRGS","IE0031619046.USD","IE00B66KJ199.SGD","CR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}